Helsinn sets up a bou­tique in­vest­ment fund with a rov­ing eye for on­col­o­gy up­starts

If you’re start­ing up an ear­ly-stage biotech fo­cused on can­cer R&D, Helsinn has set up a bou­tique ven­ture arm that just might be in­ter­est­ed in step­ping in at the ground floor.

Un­til now, the Swiss com­pa­ny has been fo­cus­ing its at­ten­tion on can­cer sup­port­ive care, pri­mar­i­ly back­ing late-stage work. But the new Helsinn In­vest­ment Fund is de­signed to join syn­di­cates with an eye for ear­ly stage plays.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER